Last reviewed · How we verify
NCT05297123
Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid
Status unknown
Phase 1
Last updated 28 March 2022
What this trial tests
Phase 1 trial testing All-trans retinoic acid in Acute Myeloid Leukemia in 30 participants. Status unknown.
Timeline
3 February 2019
Primary endpoint
3 December 2023
3 December 2023
31 December 2023
Quick facts
| Lead sponsor | First Affiliated Hospital Xi'an Jiaotong University |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 3 February 2019 |
| Primary completion | 3 December 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- All-trans retinoic acid
- Arsenic Trioxide (ARSENIC TRIOXIDE) — full drug profile →
- Realgar-Indigo naturalis formula
Conditions studied
- Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →
Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Who can join
18 and older, any sex, with Acute Myeloid Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The clinical trial was designed to prove that Arsenic plus ATRA possibly had an effect on improving the symptoms, reducing the early mortality rate and prolonging the total survival time of patients with newly diagnosed or relapsed AML.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
The Promise of Retinoids in the Treatment of Cancer: Neither Burnt Out Nor Fading Away.
Nagai Y, Ambinder AJ. · · 2023 · cited 23× · PMID 37509198 · DOI 10.3390/cancers15143535 -
Arsenic Trioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 Activation.
Hoang DH, Buettner R, Valerio M, Ghoda L, et al · · 2022 · cited 22× · PMID 35743010 · DOI 10.3390/ijms23126568 -
All-trans retinoic acid in hematologic disorders: not just acute promyelocytic leukemia.
Chen Y, Tong X, Lu R, Zhang Z, et al · · 2024 · cited 16× · PMID 39027338 · DOI 10.3389/fphar.2024.1404092 -
Impact of p53-associated acute myeloid leukemia hallmarks on metabolism and the immune environment.
Chomczyk M, Gazzola L, Dash S, Firmanty P, et al · · 2024 · cited 6× · PMID 39161899 · DOI 10.3389/fphar.2024.1409210 -
Acute promyelocytic leukemia with <i>TTMV::RARA</i> fusion potentially responds to all-<i>trans</i> retinoic acid/arsenic trioxide treatment.
Xu Q, Peng Y, Sun S, Zhang Y, et al · · 2025 · cited 3× · PMID 39844766 · DOI 10.3324/haematol.2024.285711
Verify or expand the search:
- PubMed search for NCT05297123
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of All-trans retinoic acid
Trials testing the same drug.
- NCT07187505 — Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia · NA · active not recruiting
- NCT06646666 — ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and AS · Phase 2 · not yet recruiting
- NCT05345002 — All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma · Phase 2 · recruiting
- NCT04700176 — A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma · Phase 2 · terminated
- NCT04793919 — Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia · Phase 2 · recruiting
Other recruiting trials for Acute Myeloid Leukemia
Currently open trials in the same condition.
- NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
- NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I · Phase 2 · recruiting
- NCT07177079 — High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML · Phase 1 · recruiting
- NCT07384715 — First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod · Phase 1 · recruiting
- NCT07107126 — Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes · Phase 1 · recruiting
Other First Affiliated Hospital Xi'an Jiaotong University trials
Trials by the same sponsor.
- NCT07389460 — Intravenous rhPro-UK Before Stroke Thrombectomy in the Extended Time Window (BRIDGE-PUK EXTEND) · Phase 3 · not yet recruiting
- NCT07170176 — Effects of PFO Closure on Glymphatic Function and Clinical Symptoms in Patients With Migraine · NA · recruiting
- NCT07168291 — Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma · EARLY_PHASE1 · not yet recruiting
- NCT06775782 — Remote Ischemic Conditioning for Acute Moderate Ischemic Stroke Due to Large Artery Atherosclerosis · NA · recruiting
- NCT07266467 — Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Dis · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT05297123 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital Xi'an Jiaotong University
- Last refreshed: 28 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05297123.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing